Company Filing History:
Years Active: 2009-2014
Title: Elisabeth Thomassen-Wolf: Innovator in Antibody Research
Introduction
Elisabeth Thomassen-Wolf is a prominent inventor based in Martinsried, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target receptor protein tyrosine kinases. With a total of two patents to her name, her work has the potential to impact various medical conditions.
Latest Patents
Thomassen-Wolf's latest patents focus on antibodies that block receptor protein tyrosine kinase activation. These patents describe molecules that comprise the antigen-binding portion of antibodies capable of blocking both constitutive and ligand-dependent activation of receptor protein tyrosine kinases, such as fibroblast growth factor receptor 3 (FGFR3). The innovative screening methods she developed utilize a soluble dimeric form of the receptor protein tyrosine kinase as a target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules identified through this process can be administered to treat or inhibit conditions such as skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases, or tumor progression associated with the constitutive activation of receptor protein tyrosine kinases.
Career Highlights
Elisabeth Thomassen-Wolf is currently associated with Fibron Limited, where she continues her research and development efforts. Her work has garnered attention in the scientific community for its potential applications in treating serious medical conditions.
Collaborations
Thomassen-Wolf has collaborated with notable colleagues, including Avner Yayon and Eran Rom, to advance her research initiatives. These collaborations have contributed to the depth and breadth of her work in antibody development.
Conclusion
Elisabeth Thomassen-Wolf is a trailblazer in the field of antibody research, with her innovative patents paving the way for new treatments in medicine. Her contributions are significant and continue to influence the biotechnology landscape.